Amneal Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Amneal Pharmaceuticals Inc in the third quarter 2026?
Amneal Pharmaceuticals Inc achieved a return on average equity (ROE) of 157.05 % in its third quarter 2026, this is above AMRX's average return on equity of 0%.
Amneal Pharmaceuticals Inc shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $112 million

While the company's net income was fading, Amneal Pharmaceuticals Inc was able to improve its ROE compared to the second quarter 2026.

Within the Major Pharmaceutical Preparations industry Amneal Pharmaceuticals Inc achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the second quarter 2026 at no. .

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	-	-	-	-	-
Y / Y Net Income Change	-	95.49 %	216.84 %	-	54.22 %
Net Income (TTM) in Millions	175	215	181	128	58
Return On Equity (TTM)	157.05 %	-	-	-	-
AMRX's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	531	33	-46	-71	-110
Seq. Equity Change	1508.7 %	-	-	-	-
Seq. Net Income Change	-	-10.75 %	57.34 %	173.4 %	-49.08 %

Back to AMRX Management Effectiveness >> AMRX's 5 Years Annual ROE >> Compare AMRX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

AMRX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	-71	-110	20	184	367
Y / Y Equity Change	-	-	-89.12 %	-49.87 %	6.39 %
Net Income in Millions	128	-74	-49	-255	20
Y / Y Net Income Change	-	-	-	-	-70.59 %
Return On Equity	-	-	-243.48 %	-138.49 %	5.5 %

Back to AMRX Management Effectiveness >> AMRX's 5 Years Annual ROE >> Compare AMRX ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 5.5 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AMRX's' Return on Equity at Yahoo Finance
AMRX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AMRX's Competitors
Subscribers only: Roe for Amneal Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for AMRX's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Alnylam Pharmaceuticals Inc	159.72 %
Alector Inc	112.21 %
Medpace Holdings Inc	99.76 %
3m Company	93.07 %
Exelixis Inc	85.83 %
Eli Lilly And Company	83.65 %
Rigel Pharmaceuticals Inc	73.94 %
Idexx Laboratories Inc	71.18 %
Tenet Healthcare Corp	57.13 %
Aurinia Pharmaceuticals Inc	51.92 %
Nurix Therapeutics Inc	49.34 %
Carlisle Companies Incorporated	44.18 %
Bristol myers Squibb Company	43.83 %
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %

Date modified: 2026-11-10T05:28:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.